A phase 3 randomized study of cabozantinib (XL184) vs everolimus in subjects with clear cell renal cell carcinoma (METEOR)

被引：0
|
作者：
Choueiri, T. K. [1 ]
Escudier, B. [2 ]
Powles, T. [3 ]
Cella, D. [4 ]
Lee, Y. [5 ]
Laird, D. A. [5 ]
Scheffold, C. [5 ]
Motzer, R. J. [6 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Inst Gustave Roussy, Dept Med Oncol, Villejuif, France
[3] Queen Mary Univ, Barts Canc Inst, London, England
[4] Northwestern Univ, Dept Med Social Sci, Feinberg Sch Med, Chicago, IL 60611 USA
[5] Exelixis Inc, San Francisco, CA USA
[6] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
BJU INTERNATIONAL | 2013年 / 112卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
7
引用
收藏
页码：4 / 4
页数：1
相关论文
共 50 条
  • [41] Phase 3 randomized, double-blind, controlled study of cabozantinib (XL184) versus placebo in subjects with hepatocellular carcinoma who have received prior sorafenib (CELESTIAL; NCT01908426).
    Abou-Alfa, Ghassan K.
    Cheng, Ann-Lii
    Meyer, Tim
    El-Khouelry, Anthony B.
    Ikeda, Masafumi
    Chun, Hoo Geun
    Falvre, Sandrine J.
    Furuse, Junji
    Knox, Jennifer J.
    Okusaka, Takuji
    Ping, Jerry
    Borgman-Hagey, Anne E.
    Kelley, Robin Kate
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [42] Phase 3 randomized, double-blind, controlled study of cabozantinib (XL184) versus placebo in subjects with hepatocellular carcinoma who have received prior sorafenib (CELESTIAL; NCT01908426)
    Abou-Alfa, Ghassan K.
    Cheng, Ann-Lii
    Meyer, Tim
    El-Khoueiry, Anthony B.
    Ikeda, Masafumi
    Chun, Hoo Geun
    Furuse, Junji
    Knox, Jennifer J.
    Okusaka, Takuji
    Ping, Jerry
    Borgman-Hagey, Anne E.
    Kelley, Robin Kate
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [43] Cabozantinib (XL184) and R428 (BGB324) Inhibit the Growth of Esophageal Squamous Cell Carcinoma (ESCC)
    Yang, Pei-Wen
    Liu, Yu-Cheng
    Chang, Ya-Han
    Lin, Ching-Ching
    Huang, Pei-Ming
    Hua, Kuo-Tai
    Lee, Jang-Ming
    Hsieh, Min-Shu
    FRONTIERS IN ONCOLOGY, 2019, 9
  • [44] Antitumor activity observed in a phase I drug-drug interaction study of cabozantinib (XL184) and rosiglitazone in patients (pts) with renal cell carcinoma (RCC) and differentiated thyroid cancer (DTC)
    Choueiri, T. K.
    Pal, S. K.
    Cabanillas, M. E.
    Ramies, D. A.
    Tseng, L.
    Holland, J. S.
    Morrissey, S.
    Dutcher, J. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [45] Efficacy of cabozantinib (cabo) vs everolimus (eve) by metastatic site and tumor burden in patients (pts) with advanced renal cell carcinoma (RCC) in the phase 3 METEOR trial
    Powles, T. B.
    Escudier, B.
    de Souza, P.
    Chowdhury, S.
    Pook, D.
    Harmenberg, U.
    Basappa, N.
    Geynisman, D.
    Merchan, J.
    Redman, B. G.
    Ryan, C.
    Goodman, O.
    Ho, T.
    Singh, P.
    Lougheed, J.
    Patel, M.
    Knox, J. J.
    Motzer, R. J.
    Choueiri, T. K.
    ANNALS OF ONCOLOGY, 2016, 27
  • [46] Efficacy of cabozantinib (C) vs everolimus (E) in patients (pts) with advanced renal cell carcinoma (RCC) and bone metastases (mets) from the phase III METEOR study
    Escudier, Bernard J.
    Powles, Thomas
    Motzer, Robert J.
    Olencki, Thomas
    Aren, Osvaldo Rudy
    Oudard, Stephane
    Bracarda, Sergio
    Tomczak, Piotr
    Castellano, Daniel E.
    Appleman, Leonard Joseph
    Drabkin, Harry A.
    Vaena, Daniel A.
    Milwee, Steven
    Youkstetter, Jillian
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [47] Evaluation of the novel "trial within a trial" design of METEOR, a randomized phase 3 trial of cabozantinib versus everolimus in patients (pts) with advanced renal cell carcinoma (RCC)
    Hessel, C.
    Mangeshkar, M.
    Motzer, R. J.
    Escudier, B.
    Powles, T. B.
    Schwab, G.
    Choueiri, T. K.
    ANNALS OF ONCOLOGY, 2016, 27
  • [48] Cabozantinib for the Management of Metastatic Clear Cell Renal Cell Carcinoma
    Del Vecchio, Sharon J.
    Ellis, Robert J.
    JOURNAL OF KIDNEY CANCER AND VHL, 2018, 5 (04): : 1 - 5
  • [49] Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
    Choueiri, Toni K.
    Escudier, Bernard
    Powles, Thomas
    Tannir, Nizar M.
    Mainwaring, Paul N.
    Rini, Brian I.
    Hammers, Hans J.
    Donskov, Frede
    Roth, Bruce J.
    Peltola, Katriina
    Lee, Jae Lyun
    Heng, Daniel Y. C.
    Schmidinger, Manuela
    Agarwal, Neeraj
    Sternberg, Cora N.
    McDermott, David F.
    Aftab, Dana T.
    Hessel, Colin
    Old, Christian Scheff
    Schwab, Gisela
    Hutson, Thomas E.
    Pal, Sumanta
    Motzer, Robert J.
    LANCET ONCOLOGY, 2016, 17 (07): : 917 - 927
  • [50] Outcomes based on age in the phase 3 METEOR trial of cabozantinib (cabo) versus everolimus (eve) in patients with advanced renal cell carcinoma (RCC).
    Donskov, Frede
    Motzer, Robert J.
    Voog, Eric
    Hovey, Elizabeth J.
    Grullich, Carsten
    Nott, Louise M.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
12345